PE20161094A1 - Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos - Google Patents

Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos

Info

Publication number
PE20161094A1
PE20161094A1 PE2016001214A PE2016001214A PE20161094A1 PE 20161094 A1 PE20161094 A1 PE 20161094A1 PE 2016001214 A PE2016001214 A PE 2016001214A PE 2016001214 A PE2016001214 A PE 2016001214A PE 20161094 A1 PE20161094 A1 PE 20161094A1
Authority
PE
Peru
Prior art keywords
sequence
dengue virus
plasmid
protein
seq
Prior art date
Application number
PE2016001214A
Other languages
English (en)
Inventor
Ada Maria De Barcelos Alves
Ricardo Galller
Marcos Da Silva Freire
Adriana De Souza Azevedo
Original Assignee
Fundação Oswaldo Cruz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43825448&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20161094(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fundação Oswaldo Cruz filed Critical Fundação Oswaldo Cruz
Publication of PE20161094A1 publication Critical patent/PE20161094A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Se refiere a un plasmido recombinante que contiene el gen de la proteina E de cada serotipo del virus del dengue fusionado a la secuencia que codifica para el peptido senal de t-PA caracterizado porque se construye insertando: a) la secuencia que codifica para el 80% de la proteina de la envuelta viral (E) del virus del dengue sin la parte C-terminal de la proteina E, tal secuencia se amplifica usando los oligonucleotidos SEQ ID NO:3 y SEQ ID NO:4; o b) la secuencia que codifica para el dominio III de la proteina E del virus del dengue; tal secuencia se amplifica usando los oligonucleotidos SEQ ID NO: 5 y SEQ ID NO: 4. La secuencia de (a) esta contenida entre los nucleotidos 937 y 2131, y la secuencia de (b) esta contenida entre los nucleotidos 1822 y 2131, del genoma completo de DENV2, cepa New Guinea C (NGC). Posteriormente se lleva a cabo la clonacion de la secuencia en el plasmido pcTPA entre los sitios enzimaticos de las enzimas de restriccion EcoRV y XbaI1
PE2016001214A 2009-10-01 2010-08-01 Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos PE20161094A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BRPI0904020A BRPI0904020B8 (pt) 2009-10-01 2009-10-01 composição vacinal contra o vírus da dengue, e, kit

Publications (1)

Publication Number Publication Date
PE20161094A1 true PE20161094A1 (es) 2016-10-22

Family

ID=43825448

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2016001214A PE20161094A1 (es) 2009-10-01 2010-08-01 Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos
PE2012000411A PE20121171A1 (es) 2009-10-01 2010-08-01 Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos

Family Applications After (1)

Application Number Title Priority Date Filing Date
PE2012000411A PE20121171A1 (es) 2009-10-01 2010-08-01 Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos

Country Status (10)

Country Link
US (1) US10357558B2 (es)
EP (1) EP2484376A4 (es)
CN (1) CN102711817B (es)
BR (1) BRPI0904020B8 (es)
CL (1) CL2012000783A1 (es)
CO (1) CO6541529A2 (es)
CU (1) CU24060B1 (es)
EC (1) ECSP12012131A (es)
PE (2) PE20161094A1 (es)
WO (1) WO2011038473A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3177574A1 (en) * 2013-03-15 2014-09-25 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
MX366154B (es) 2013-06-21 2019-06-28 Merck Sharp & Dohme Composiciones de vacuna del virus del dengue y metodos de uso de las mismas.
ITRM20130458A1 (it) 2013-08-05 2015-02-05 Internat Ct For Genetic En Gineering And Vaccino genetico anti-dengue virus basato sugli ectodomini della proteina envelope
EP3236997B1 (en) * 2014-12-22 2024-05-29 Merck Sharp & Dohme LLC Dengue virus vaccine compositions and methods of use thereof
US20220226401A1 (en) 2018-09-05 2022-07-21 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6455509B1 (en) * 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
US6962708B1 (en) * 1997-02-28 2005-11-08 Acambis, Inc. Chimeric flavivirus vaccines
BRPI9701774B8 (pt) 1997-04-11 2015-09-29 Fundação Oswaldo Cruz Fiocruz cdna mutante e infeccioso do vírus da febre amarela, constructo de dna, vírus recombinante de febre amarela e vacina para humanos contra infecções de febre amarela.
US6881723B1 (en) * 1998-11-05 2005-04-19 Powderject Vaccines, Inc. Nucleic acid constructs
WO2003102166A2 (en) * 2002-02-26 2003-12-11 Maxygen, Inc. Novel flavivirus antigens
CA2618783A1 (en) 2005-08-10 2007-02-22 Acambis Inc. Vaccination against dengue virus infection
CN101287490B (zh) * 2005-08-10 2013-04-24 阿坎姆比斯公司 对抗登革热病毒感染的疫苗接种
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
EP2462930B1 (en) * 2006-11-09 2017-05-31 The United States Of America As Represented By The Secretary Of The Navy Induction of an immune response against dengue virus using prime-boost approach
KR101686942B1 (ko) * 2008-01-11 2016-12-28 이노비오 파마수티컬즈, 인크. 뎅기 바이러스 다중 서브타입에 대항하는 신규한 백신

Also Published As

Publication number Publication date
CU24060B1 (es) 2014-12-26
WO2011038473A8 (pt) 2012-07-19
BRPI0904020A2 (pt) 2011-06-14
PE20121171A1 (es) 2012-08-30
CL2012000783A1 (es) 2013-03-22
WO2011038473A1 (pt) 2011-04-07
CN102711817A (zh) 2012-10-03
CO6541529A2 (es) 2012-10-16
ECSP12012131A (es) 2013-02-28
EP2484376A4 (en) 2014-01-22
EP2484376A1 (en) 2012-08-08
CU20120057A7 (es) 2013-01-30
CN102711817B (zh) 2016-10-26
BRPI0904020B8 (pt) 2021-05-25
US20120251570A1 (en) 2012-10-04
US10357558B2 (en) 2019-07-23
BRPI0904020B1 (pt) 2019-11-12

Similar Documents

Publication Publication Date Title
PE20161094A1 (es) Metodo, kit, plasmido y composicion para inducir una respuesta inmunitaria contra el virus del dengue basandose en vacunas de adn y virus quimericos
Li et al. A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques
MX2019010275A (es) Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este.
NZ593598A (en) Optimized antiviral vaccines with improved cellular immunogenicity
AR044724A1 (es) Promotores del virus de la rizadura amarilla del cestrum
WO2009124312A3 (en) Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
CL2010000883A1 (es) Acidos nucleicos que comprenden secuencias de un virus de gastroenteritis transmisible (tgev), secuencias que codifican epitopes neutralizadores de orf5 de prrsv y al menos otro peptido capaz de aumentar una respuesta inmune contra prrsv; vector , celula, particula viral, vacuna y composicion que lo comprenden; polipeptido codificado
MXPA02006888A (es) Flavivirus recombinantes y metodos para utilizar los mismos.
MX339241B (es) Vacunas novedosas contra sub-tipos multiples de virus de influenza.
NO20056074L (no) Hoy titer rekombinante influensavira til vaksiner og genterapi
CO6290791A2 (es) Vacunas y composiciones inmunogénicas que contienen nuevas cepas del circo virus porcino tipo 2b para inmunizar cerdos contra pmws
CY1105680T1 (el) Μολυσματικος κλωνος cdna βορειοαμερικανικου ιου χοιρειου αναπαραγωγικου και αναπνευστικου συνδρομου (prrs) και χρησεις αυτου
MX2021015465A (es) Vacuna para fiebre porcina africana.
JP2009544333A5 (es)
MX340880B (es) Vacunas mejoradas y metodos para uso de las mismas.
NZ580378A (en) Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells
PE20090683A1 (es) Peptidos de senalizacion
EA202092990A2 (ru) Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
CL2009001249A1 (es) Uso de una enzima pectonilitica endopoligalacturonasa para tratar pure de frutas o verduras; procedimiento para tratamiento enzimatico; molecula de adn que codifica un polipeptido con actividad endopoligalacturonasa; polipeptido, vector de expresion y celula huesped que comprende dicha secuencia.
WO2014205579A4 (en) Modified matrix proteins of vesicular stomatitis virus
TW201008576A (en) New fusion proteins and their use for the preparation of vaccines against hepatitis C
CU23245A1 (es) CADENAS QUIMéRICAS CODIFICANTES PARA PROTEINAS INDUCTORAS DE EFECTOS CONTRA VIRUS. PREPARADOS UTILIZANDO PROTEINAS QUIMéRICAS
EP1816203A4 (en) FOR CORONAVIRUS-SIMILAR PARTICLES CODING EXPRESSION VECTOR
Norouzian et al. Phylogenetic analysis of hemagglutinin gene of H9N2 avian influenza viruses isolated from chicken in Iran in 2010-2011: emerging of a new subgroup